Lead Inventor

Dimiter Dimitrov

16 results

(0.05 seconds)

Human Monoclonal Antibodies against SARS-CoV-2

05259

Neutralizing human monoclonal antibodies target SARS-CoV-2 spike RBD, blocking entry or directing infected-cell killing.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Covid-19
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Chuan Chen
Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-02-26

uPAR-Targeting Human Antibody for Treating Cancer and Fibrotic Diseases

06240

uPAR-targeting human VH antibodies offer potent, versatile cancer/fibrosis therapy with VH-Fc fusion for enhanced stability and penetration.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Hepatology
Oncology
Therapeutic Indications: Gastric Cancer / Intestinal Adenocarcinoma
Melanoma
Pancreatic adenocarcinoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Xiaojie Chu
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-12-06
Collections: Cardiometabolic
Women's & Reproductive Health

Fully Human Anti-FLT3 (CD135) Antibodies for Leukemia

05621

Fully human anti-FLT3 antibodies discovered for broad cancer targets; potential for enhanced tumor penetration and safer immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - scFV
Therapeutic Areas: Oncology
Therapeutic Indications: Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Terry Fry
Wei Li
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-02-18
Collections: Women's & Reproductive Health

Fully Human Antibodies Targeting Membrane Proximal Region in Human CEACAM5

05469

Fully human CEACAM5-targeting antibody binds membrane-proximal region with high specificity, enabling CAR-T/biotherapeutic cancer therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-08-06

In Vivo–Validated Anti-CD276 (B7-H3) VH-Domain/Fab Antibodies

04890

Novel fully human VH-domain and Fab antibodies target CD276 (B7-H3) for versatile solid-tumor immunotherapy and enhanced penetration.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Bispecific
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Wei Li
John W. Mellors
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-02-11

Multi-Mechanism Anti-CD276 (B7-H3) Antibodies for Solid Tumors

06094

Engineered anti-CD276 antibodies (eVHd, Fabs) offer small, human, multi-epitope tumor-targeting immunotherapy with enhanced penetration.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Melanoma
Glioblastoma
Prostate cancer / adenocarcinoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Dontcho V. Jelev
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-07-06

PSMA with Multiple Single-Chain and Domain Binders Treats Prostate Cancer

05717

PSMA-targeting small VH-domain antibodies enable potent ADC/ADCC/CAR-T therapies with enhanced tumor penetration and distinct epitopes.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-06-09

Fully Human Anti-Mesothelin Engineered Antibody VH Domains

05170

Fully human VH-domain CAR-T targets mesothelin tumors; smaller, potentially less immunogenic, improved penetration and cryptic-epitope access.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - scFV
Therapeutic Areas: Oncology
Therapeutic Indications: Pancreatic adenocarcinoma
Ovarian cancer
Mesothelioma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
John W. Mellors
Zehua Sun
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-11-15
Collections: Women's & Reproductive Health

Antibody Domains that bind to Neutrophil Elastase (NE) polypeptides

05643

Antibody domains target neutrophil elastase to inhibit its activity, enabling cancer and inflammatory-disease immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Ductal carcinoma (Breast cancer)
Lung cancer - other
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Xiaojie Chu
Dimiter Stanchev Dimitrov
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-03-17
Collections: Women's & Reproductive Health

Identification of Fully Human anti-PSCA Antibodies

05676

Fully human anti-PSCA antibodies enable targeted therapy and ADCs for PSCA-expressing prostate and other solid tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Pancreatic adenocarcinoma
Renal cell carcinoma (RCC)
Urothelial carcinoma (Bladder cancer)
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-04-21

Fully Human Anti-cluster of Differentiation-22 (CD22) Engineered Antibody VH Domains

05831

Small, fully human anti-CD22 VH domains offer targeted B-cell cancer therapy with improved penetration and reduced immunogenicity.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - scFV
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Leukemia
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
John W. Mellors
Zehua Sun
Date Submitted: 2021-10-06

Fully Human Fabs Binding to the CD94/NKG2A Heterodimer

05650

Fully human antibodies block CD94/NKG2A, restoring NK/T cell activity, with cancer and HIV therapeutic potential.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Infectious Disease
Oncology
Therapeutic Indications: HIV
Lung Cancer - Non-Small Cell
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Yae Jin Kim
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-03-23
Collections: Women's & Reproductive Health

Fully Human FAbs to IGF-1 and IGF-2

04929

Fully human IGF-1/IGF-2–binding Fabs block IGF signaling to curb cancer cell growth, offering novel therapeutics.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Colorectal cancer (CRC)
Prostate cancer / adenocarcinoma
Ductal carcinoma (Breast cancer)
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-03-24
Collections: Women's & Reproductive Health

Novel Human Antibodies Targeting ENPP1

05859

Fully human anti-ENPP1 antibodies stimulate tumor cell death and boost immunotherapy across multiple cancers.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Immunology
Oncology
Therapeutic Indications: Ductal carcinoma (Breast cancer)
Solid tumor
Lung cancer - other
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Xiaojie Chu
Dimiter Stanchev Dimitrov
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-10-30
Collections: Women's & Reproductive Health

Fully Human Fabs to CD22 (bCAT1)

04874

Fully human anti-CD22 D7 binders enable CAR-T and ADCs for B-cell cancers, targeting proximal epitopes for enhanced efficacy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Lymphoma
Leukemia
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-01-27

Human Antibodies Identified as Brain Cancer Immunotherapy Targets

05700

Eight human antibody domains target protogenin to curb pediatric medulloblastoma growth, offering promising brain-cancer immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Therapeutic Indications: Brain cancer - Other
Diffuse intrinsic pontine gliomas (DIPG)
Medulloblastoma
Tags: Pediatrics
Rare disease
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Chuan Chen
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-05-25
Collections: Cell & Gene Therapy